As the US Supreme Court mulls the so-called pay-for-delay schemes of the pharmaceutical industry, major drugstore retail chain Walgreen Co. has reportedly acquired a majority ownership stake of a pharmaceutical wholesaler, giving Walgreens a major upper-hand when negotiating drug prices. Walgreens currently has a supply agreement with AmerisourceBergen Corp. in a 10-year deal. Now, Walgreens will hold a majority stake in the company, while European retailer Alliance Boots will hold a minority stake. The contract allows Walgreens and Boots to buy up to 7 percent of AmerisouceBergen’s shares as well as warrants to pursue another 16 percent. The deal is just a further expansion of Walgreen’s $7 billion investment in global expansion; if Walgreens pursues its ability to purchase another 16 percent in 2015, the chain will have fully acquired AmerisourceBergen. The pharmaceutical wholesaler supplies brand name and generic drugs to Walgreens.
Featured News
Fox News Seeks Dismissal of Newsmax Antitrust Case in Florida
May 10, 2026 by
CPI
India Orders Antitrust Probe Into Pernod Ricard Over Retail Practices
May 10, 2026 by
CPI
Ace Hardware Faces Federal Lawsuit Alleging Nationwide Price-Fixing Scheme
May 10, 2026 by
CPI
EU Grants Google More Time in Ongoing Digital Competition Probe
May 10, 2026 by
CPI
DOJ, States Reach Antitrust Deal With Agri Stats Aimed at Lowering Meat Prices
May 10, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Unilateral Effects
Apr 28, 2026 by
CPI
A Net Present Value Approach to Merger Analysis
Apr 28, 2026 by
Joseph J Simons & Malcolm Coate
Generative AI and Competitive Disruption: Increasingly Relevant for Merger Analysis?
Apr 28, 2026 by
Andrea Coscelli, Emily Chissell, Nitika Bagaria & Tega Akati-Udi
Non-Price Unilateral Effects In Media Mergers
Apr 28, 2026 by
Lapo Filistrucchi & Teresa Oriani
Ecosystem Mergers and Unilateral Effects? A Framework for Assessing the Ecosystem Theory of Harm
Apr 28, 2026 by
Ethel Fonseca, George Tucker & Helder Vasconcelos